Updated:
Abiomed
Abiomed builds the Impella heart pump for circulatory support, with a focus on heart recovery and clinical research.
Abiomed
Abiomed, founded in 1981, is a medical technology company focused on heart and lung recovery. The firm's Impella heart pump platform is designed to provide hemodynamic support, allowing the heart to rest and recover. Its executive team sets strategic direction, with headquarters in Danvers, Massachusetts, and additional offices in Germany, Japan, Maryland, and Massachusetts. Abiomed's product portfolio centers on percutaneous catheter-based heart pumps and related clinical support services. The company invests in clinical research and future innovations, aiming to develop smaller, smarter, more connected technology. Geographic footprint includes North America, Europe, and Asia. Portfolio companies include the Impella product line and related services. Abiomed does not publicly disclose team size or assets under management. It operates as a public company (ticker: ABMD) with a focus on shareholder value. The firm sponsors a community platform, HeartRecovery.com, for Protected PCI. Abiomed operates as a publicly traded medical device company rather than a family office or investment firm. Its structure is shaped by regulatory requirements for medical devices and clinical research mandates. The firm prioritizes patient outcomes and clinical data over other investment theses.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Danvers
Corporate office
22 Cherry Hill Drive, Danvers, Massachusetts 01923, United States
Additional offices
Aachen, Germany · Tokyo, Japan · Berlin, Germany · Halethorpe, Maryland, United States · Woburn, Massachusetts, United States
Frequently asked questions
Who runs investment decisions at Abiomed?
Abiomed is a publicly traded company (ABMD) governed by a board of directors and executive team. The CEO and CFO lead capital allocation decisions. The firm does not disclose a dedicated investment committee separate from its executive leadership.
How does Abiomed source proprietary deal flow?
Abiomed does not operate as a family office or investment firm; it is a medical device company. Its 'deal flow' consists of internal R&D projects, clinical trials, and partnerships with healthcare institutions. It does not participate in third-party venture capital or private equity investments.
Is Abiomed structured as a single family office or does it operate more like a venture firm?
Abiomed is neither a family office nor a venture firm. It is a publicly traded medical technology corporation (NASDAQ: ABMD) focused on heart pump manufacturing and clinical support. It does not manage outside capital or make investments in other companies.
What investment stages does Abiomed typically target?
Abiomed does not target investment stages. It develops, manufactures and sells its own medical devices. The company may engage in clinical research partnerships or strategic collaborations, but these are operational rather than investment-driven.
Which sectors does Abiomed explicitly avoid?
Abiomed avoids all sectors outside cardiovascular and respiratory medical technology. It does not invest in software, financial services, real estate or other industries. The firm maintains a narrow focus on heart and lung recovery.
How is Abiomed related to Johnson & Johnson?
Abiomed is not directly related to Johnson & Johnson MedTech as of the latest public information. However, J&J MedTech has referenced Impella products in its press releases (per Johnson & Johnson, October 2025). No acquisition or partnership has been announced.
Does Abiomed maintain philanthropic structures, and how are they separated?
Abiomed does not disclose a separate philanthropic foundation. Its corporate social responsibility activities are embedded in its Patients First culture and clinical research commitments. The company does not separate charitable activities into a distinct entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: